A Practical Approach to Disorders of Hypopigmentation

Hypopigmentation refers to reduced skin pigmentation, whereas depigmentation denotes complete pigment absence. In hypopigmentation, melanocytes are present but exhibit decreased melanin production or impaired melanosome transfer; depigmented lesions reflect loss of functional melanocytes, as in vitiligo. Distinguishing these entities narrows the differential and guides evaluation. Hypopigmented macules and patches arise from congenital disorders, acquired pigmentary abnormalities, and inflammatory dermatoses. This review provides a clinically focused overview, highlighting features that facilitate accurate diagnosis.

Approach to the Patient with Hypopigmentation

Evaluation of hypopigmentation begins with a careful history and physical examination. Key considerations include age of onset, lesion distribution, morphology, stability versus progression, and the presence of associated systemic findings. Diagnostic tools may include Wood’s lamp examination, dermoscopy, histopathology, genetic testing, and targeted laboratory studies when indicated. Wood’s lamp examination can distinguish between depigmentation and hypopigmentation. Depigmented lesions demonstrate bright accentuation due to the absence of melanin, whereas hypopigmented lesions show more subtle enhancement.

Congenital Disorders of Hypopigmentation

Congenital hypopigmentation encompasses a heterogeneous group of conditions presenting at birth or early in life, resulting from abnormalities in melanocyte development, melanin synthesis, or pigment distribution. These disorders can be broadly categorized into pigmentary dilution disorders, mosaic pigmentary disorders, and localized congenital hypopigmented lesions.

Pigmentary Dilution Disorders

Pigmentary dilution disorders comprise a group of inherited conditions characterized by reduced melanin production, abnormal melanosome formation or transport, or impaired melanocyte development, resulting in generalized or localized hypopigmentation of the skin, hair, and eyes. These disorders are typically caused by single-gene mutations that disrupt key steps in melanocyte biology and melanogenesis.

Oculocutaneous Albinism 

Pigmentary dilution disorders can be classified based on the level of disruption within the pigmentation pathway. Disorders of melanin synthesis, such as Oculocutaneous albinism (types 1–4), result from defects in tyrosinase or related enzymes and present with diffuse hypopigmentation of the skin, hair, and eyes, often accompanied by ocular findings including nystagmus, photophobia, and reduced visual acuity.1

Hermansky-Pudlak Syndrome and Chédiak-Higashi Syndrome 

Disorders of melanosome formation include Hermansky-Pudlak syndrome (HPS) and Chédiak-Higashi syndrome (CHS), both of which involve abnormalities in lysosome-related organelles. HPS is characterized by pigmentary dilution in association with bleeding diathesis due to absent platelet dense granules and, in some subtypes, pulmonary fibrosis and immunodeficiency. CHS results from impaired lysosomal trafficking and presents with partial albinism, recurrent infections, and progressive neurologic dysfunction.¹

Griscelli Syndrome

Disorders of melanosome transport, such as Griscelli syndrome, arise from defects in the intracellular movement of melanosomes, leading to pigmentary dilution.2 A distinguishing feature is the presence of large, irregular pigment clumps within hair shafts on light microscopy, reflecting abnormal melanosome distribution.

Mosaic Disorders of Hypopigmentation

Linear and Whorled Nevoid Hypopigmentation 

Linear and whorled nevoid hypopigmentation (LWNH), also referred to as "hypomelanosis of Ito", describes hypopigmented streaks and whorls following the lines of Blaschko. This pattern reflects underlying genetic mosaicism rather than a single disease entity. The hypopigmented areas represent a genetically distinct clone of cells, and extracutaneous manifestations may be present. Common sites include the trunk, back, buttocks, and extremities. The hypopigmentation is stable and nonprogressive, distinguishing it from vitiligo.³

Neurologic involvement is common and most frequently manifests as cognitive impairment, followed by seizures, developmental delay, and abnormalities in muscle tone. Reported findings include intellectual disability, seizure disorders, and structural brain anomalies. Hemimegalencephaly has been described, often involving the cerebral hemisphere contralateral to the cutaneous hypopigmentation.⁴ Additional features may include leukoencephalopathy and a range of neurodevelopmental delays. Notably, the extent of neurologic involvement appears to parallel the distribution of cutaneous lesions, with more widespread skin involvement associated with a higher likelihood of extracutaneous abnormalities.⁵

Musculoskeletal involvement is well described in LWNH and encompasses a spectrum of abnormalities, including facial and limb hypoplasia, hemihypertrophy, and skeletal asymmetry. Reported findings also include ipsilateral pes cavus and a variety of limb deformities.⁶

Incontinentia Pigmenti 

Incontinentia pigmenti is an X-linked dominant neurocutaneous disorder caused by loss-of-function mutations in the IKBKG gene (formerly NEMO), resulting in dysregulation of the NF-κB signaling pathway.⁶ The condition predominantly affects females and is typically lethal in males in utero.

Cutaneous manifestations progress through four well-described stages, with the fourth and final stage corresponding to a hypopigmented phase. Stage IV, also known as hypopigmented incontinentia pigmenti, typically emerges following the gradual fading and resolution of the hyperpigmentation seen in Stage III, and most commonly becomes apparent during adolescence or early adulthood.⁷ Clinically, Stage IV is characterized by linear, hypopigmented, atrophic streaks or patches distributed along the lines of Blaschko.⁶ These areas may persist indefinitely and can represent the only residual cutaneous finding in affected adult women.

Localized Congenital Hypopigmentation

Localized congenital hypopigmented lesions are typically identified at birth or early in life and are characterized by stability over time, helping to distinguish them from acquired depigmenting disorders. Among the most common entities in this category are nevus depigmentosus and ash-leaf macules, both of which require careful clinical evaluation to avoid misdiagnosis.

Nevus Depigmentosus 

Nevus depigmentosus presents as a well-defined hypopigmented patch, often with irregular or serrated borders.⁸ Lesions are usually solitary but may be multiple, and they remain stable in size and distribution relative to body growth. A characteristic feature is the potential for peripheral “splitting” into smaller macules that can be visualized under dermoscopy.⁹ Under Wood’s lamp examination, these lesions show off-white accentuation rather than the bright fluorescence seen in vitiligo. Histologically, melanocyte number is typically normal, with reduced melanin production or impaired melanosome transfer accounting for the hypopigmented appearance. 

Nevus Anemicus

Nevus anemicus is characterized by a localized, unilateral hypopigmented patch with irregular borders, most commonly involving the trunk. The lesion results from localized hypersensitivity of cutaneous blood vessels to catecholamines, leading to persistent vasoconstriction rather than a primary pigmentary abnormality.⁶ It becomes more apparent when the surrounding skin undergoes vasodilation, such as with heat or emotional stress, and disappears with diascopy, a distinguishing clinical feature. 

Tuberous Sclerosis Complex

Ash-leaf macules are hypopigmented, often ovoid lesions that represent one of the earliest cutaneous manifestations of tuberous sclerosis complex. Although they may be present at birth, they are often more readily appreciated later in infancy, particularly with Wood’s lamp examination. The presence of three or more ash-leaf macules should prompt evaluation for associated systemic findings, including neurologic and renal involvement.

Distinguishing these entities from early vitiligo is critical. Unlike vitiligo, congenital lesions are typically stable, lack complete depigmentation, and do not demonstrate progressive enlargement or the development of new lesions over time.

Inflammatory and Autoimmune Causes of Hypopigmentation

Inflammatory and autoimmune causes of hypopigmentation result from inflammation-related disruption of melanocyte function or melanin transfer, with clinical context guiding diagnosis (Table 1).

Hypopigmentation Secondary to Infectious Causes

Tinea Versicolor

Tinea versicolor is caused by Malassezia species, most notably M. globosa, M. sympodialis, and M. furfur.⁶ It presents with well-demarcated macules and patches that may be hypopigmented, hyperpigmented, or erythematous, most commonly affecting seborrheic areas such as the chest, back, neck, and proximal upper extremities.

Hypopigmentation in tinea versicolor occurs through multiple mechanisms. Dicarboxylic acids produced by Malassezia, particularly azelaic acid, inhibit tyrosinase activity and disrupt melanin synthesis.¹⁰ In addition, malassezin, a tryptophan-derived metabolite, has been shown to induce melanocyte apoptosis via activation of the aryl hydrocarbon receptor, contributing to pigment loss.¹¹

Leukoderma Syphiliticum

Leukoderma syphiliticum is an uncommon manifestation of secondary syphilis characterized by patchy hypopigmentation occurring weeks after primary infection.¹² Unlike vitiligo, the underlying mechanism is not melanocyte destruction. Instead, impaired melanogenesis appears to predominate, with ultrastructural studies demonstrating preserved melanocyte density but reduced melanin production and smaller melanosomes.¹³

Leprosy

Hypopigmented lesions accompanied by sensory impairment represent a hallmark feature of leprosy, reflecting infection with Mycobacterium leprae involving both the skin and peripheral nerves. The earliest presentation may be hypopigmented macules that may be multiple and ill-defined; they may be difficult to recognize particularly in lightly pigmented skin.6 The primary areas involved include the face, extremities, and buttocks while the warmer parts of the body are usually spared. Later, plaques or nodules present with diffuse dermal infiltration. The hypopigmentation results from bacillary infiltration and nerve damage, with the key distinguishing feature being impaired sensation (pinprick or light touch) within the hypopigmented patches.3 Diagnosis is established by the presence of at least one of three cardinal features: sensory loss within hypopigmented or erythematous lesions, enlargement of peripheral nerves with associated neurologic deficits, or identification of acid-fast bacilli on slit-skin smear microscopy^.14

Leishmaniasis

Hypopigmentation in leishmaniasis is most commonly observed in two distinct settings: post–kala-azar dermal leishmaniasis (PKDL), which arises as a cutaneous sequela of visceral leishmaniasis, and as residual dyspigmented scarring following resolution of cutaneous leishmaniasis.¹⁵ The clinical presentation and underlying mechanisms differ between these entities.

PKDL develops in a subset of patients following treatment of visceral leishmaniasis due to Leishmania donovani, with onset typically occurring months to years after systemic disease, depending on geographic region.¹⁵ In endemic areas of Asia, hypopigmented macules represent the predominant presentation, whereas papular and nodular lesions are more frequently observed in African populations. Lesions often begin in a perioral or truncal distribution and may gradually become more widespread.

The pathogenesis of hypopigmentation in PKDL is thought to involve immune-mediated melanocyte injury. Studies have demonstrated a marked reduction or absence of melanocytes within affected skin, accompanied by decreased expression of key melanogenic markers, including tyrosinase and microphthalmia-associated transcription factor (MITF).¹⁶ This process is driven by a proinflammatory milieu characterized by CD8+ T-cell activation and cytokine release, resulting in impaired melanocyte function and survival.

In contrast, hypopigmentation associated with cutaneous leishmaniasis typically reflects post-inflammatory change following lesion resolution. Healed lesions often leave atrophic scars with a hypopigmented center and a surrounding rim of hyperpigmentation, corresponding to prior sites of ulceration and tissue damage.

Tuberculosis

Cutaneous tuberculosis typically presents as chronic plaques or nodules, such as in lupus vulgaris, which may heal with residual hypopigmented scarring. The pigmentary alteration is primarily secondary to chronic inflammation and subsequent disruption of melanocyte function. Given its infectious etiology, diagnosis requires microbiologic confirmation, and management necessitates appropriate systemic antitubercular therapy. Notably, certain antitubercular agents have also been associated with drug-induced hypopigmentation, including reports of a lupus-like or butterfly-pattern hypopigmented facial eruption.¹⁷

Iatrogenic Causes of Hypopigmentation

Iatrogenic hypopigmentation encompasses pigmentary alterations resulting from medical or cosmetic interventions and is an important, often preventable, cause of acquired hypopigmentation. These changes typically arise from melanocyte toxicity, suppression of melanogenesis, or direct melanocyte destruction, and may be transient or permanent depending on the depth and mechanism of injury.

Common causes include corticosteroid-induced hypopigmentation, which may occur following topical use or intralesional injection. This is thought to result from inhibition of melanocyte function and melanogenesis rather than melanocyte loss and may present as localized or linear areas of hypopigmentation corresponding to area of application.¹⁸

Procedural interventions are also a frequent contributor. Laser therapies (particularly ablative and pigment-targeting devices), cryotherapy, chemical peels, and dermabrasion can disrupt melanocytes or the epidermal melanin unit, leading to post-procedural hypopigmentation.¹⁹ The risk is increased in individuals with darker skin types and with more aggressive treatment parameters.

Most cases of iatrogenic hypopigmentation improve spontaneously when the causative agent is discontinued, though permanent changes can occur with complete melanocyte destruction. Recognition of iatrogenic hypopigmentation is essential, as these changes can mimic pigmentary disorders such as vitiligo. A thorough treatment history, including prior procedures and medication use, is critical for accurate diagnosis and management.

Miscellaneous

Idiopathic Guttate Hypomelanosis

Idiopathic guttate hypomelanosis (IGH) is a common acquired cause of hypopigmentation, with prevalence increasing markedly with age, affecting up to 80% of individuals over 70 years. It occurs across all skin types and racial groups, although lesions are often more clinically apparent in individuals with darker pigmentation.6 Clinically, IGH is characterized by multiple discrete, well-circumscribed porcelain-white macules, typically measuring 2 mm to 6 mm in diameter, although larger lesions may occasionally be observed. The lesions are asymptomatic, non-scaly, and smooth, without associated atrophy, and are often sharply demarcated along skin furrows. They remain stable over time, without enlargement or coalescence, and spontaneous repigmentation is not observed. Hair within affected areas typically retains normal pigmentation in contrast to vitiligo. IGH most commonly involves chronically sun-exposed sites, particularly the extensor surfaces of the forearms and shins, with less frequent involvement of other extremities and rare involvement of the face.

Progressive Macular Hypomelanosis

Progressive macular hypomelanosis is a relatively common acquired hypopigmented disorder that predominantly affects young women with darker skin types, particularly in tropical or subtropical climates. It is characterized by ill-defined, non-scaly hypopigmented macules and patches, most commonly involving the trunk, with occasional extension to proximal extremities. Macules and patches may coalesce centrally and are typically asymptomatic, without preceding inflammation; features that often lead to misdiagnosis as tinea versicolor. Increasing evidence supports a role for Cutibacterium acnes (particularly phylotype III) in disease pathogenesis, which may account for the characteristic truncal distribution.6

Arsenic-induced Hypomelanosis

Arsenic-induced hypomelanosis, also referred to as leucomelanosis, is a characteristic cutaneous manifestation of chronic arsenic exposure. It presents as macular areas of decreased pigmentation, often interspersed with hyperpigmented lesions, producing the classic “raindrops on a dusty road” appearance.6 These pigmentary alterations typically occur in conjunction with other dermatologic features of chronic arsenicosis. Although hyperpigmentation is the most common cutaneous finding, the presence of mixed hyper- and hypopigmented macules is considered highly suggestive of arsenic toxicity. The pigmentary changes develop gradually following prolonged exposure, most commonly through contaminated drinking water or, less frequently, medicinal sources.²⁰ 

Management of Hypopigmentation

Management of hypopigmentation is guided by determining the diagnosis and understanding the underlying etiology. Treatment may involve a combination of topical therapies, phototherapy, laser-based interventions, surgical approaches, and, in select cases, emerging systemic agents. Treatment strategies differ depending on whether hypopigmentation is post-inflammatory or related to primary pigmentary or systemic disorders.

Topical corticosteroids and calcineurin inhibitors are commonly employed as first-line therapies, particularly in inflammatory or immune-mediated conditions, where they function to reduce inflammation and support repigmentation.

Phototherapy remains a cornerstone of treatment for many hypopigmentation disorders. Narrowband ultraviolet B (NB-UVB, 311 nm) is the most widely utilized modality, offering efficacy comparable to psoralen plus UVA (PUVA) with a more favorable safety profile. Targeted phototherapy, including the 308-nm excimer laser, allows for localized treatment of affected areas, with treatment regimens tailored based on disease extent and response.

Laser-based therapies, particularly fractional ablative and non-ablative resurfacing techniques, have demonstrated benefit in select conditions. However, care should be exercised, especially in skin of color populations, to prevent post-procedural dyspigmentation. Combination approaches (eg, fractional laser with topical prostaglandin analogues) may enhance repigmentation versus monotherapy.²¹

Conclusion

Hypopigmentation comprises a broad spectrum of disorders characterized by decreased pigmentation in the presence of intact but functionally impaired melanocytes. Distinguishing hypopigmentation from depigmentation is a critical first step that narrows the differential and guides evaluation. Accurate diagnosis relies on a structured approach integrating age of onset, morphology, distribution, progression, and associated features. While congenital forms are typically stable, acquired causes include infectious, inflammatory, autoimmune, and iatrogenic etiologies. Given the frequent clinical overlap with primary pigmentary disorders, careful clinicopathologic correlation is often required. A systematic, evidence-based approach remains essential for precise diagnosis and optimal management.